Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydralazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.93 |
| ▸ | NPC1 | O15118 | 4/20 | 0.93 |
| ▸ | RAB9A | P51151 | 4/20 | 0.93 |
| ▸ | GOT1 | P17174 | 3/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.93 |
| ▸ | TP53 | P04637 | 2/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.93 |
| ▸ | MAOA | P21397 | 2/20 | 0.93 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.93 |
| ▸ | MPO | P05164 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.93 |
| ▸ | PKM | P14618 | 1/20 | 0.93 |
| ▸ | THPO | P40225 | 1/20 | 0.93 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.93 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.93 |
| ▸ | MAPT | P10636 | 3/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydralazine SCHEMBL3995896 | 0.96 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL7810 | 0.96 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL27864907 | 0.94 | GOT1 (1.00) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL36271 | 0.94 | GOT1 (1.00) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL1173534 | 0.94 | GOT1 (1.00) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Dihydralazine SCHEMBL13724517 | 0.93 | ALDH1A1 (0.93) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL2780318 | 0.91 | ALDH1A1 (0.89) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL2781885 | 0.86 | NPC1 (0.81) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL8703662 | 0.86 | ALDH1A1 (0.81) | ALDH1A1NPC1RAB9AGOT1LMNA | |
| Hydralazine SCHEMBL2779460 | 0.86 | NPC1 (0.81) | ALDH1A1NPC1RAB9AGOT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114470-A1 | THERAPY FOR POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF MASSACHUSETTS | 2025-04-10 | — | — | US | disclosed |
| CN-118765915-A | Application of isoniazid and/or hydralazine in preventing and treating wheat stem basal rot | 德州学院 | 2024-10-15 | — | — | CN | disclosed |
| EP-1951210-B1 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | RECRO GAINESVILLE LLC (US) | 2018-12-05 | — | — | EP | disclosed |
| WO-2018149978-A1 | ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-23 | — | — | WO | disclosed |
| EP-2387396-B1 | AGENT FOR PREVENTING AND TREATING PITYRIASIS VERSICOLOR | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2017-11-15 | — | — | EP | disclosed |
| US-20170209381-A1 | Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride | SOCIETAL CDMO GAINESVILLE, LLC | 2017-07-27 | — | — | US | disclosed |
| US-9694010-B2 | Therapeutic formulation and methods of treatment | MACUCLEAR, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9463166-B2 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | RECRO GAINESVILLE LLC (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160256400-A1 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | SOCIETAL CDMO GAINESVILLE, LLC | 2016-09-08 | — | — | US | disclosed |
| US-20160151368-A1 | THERAPEUTIC FORMULATION AND METHODS OF TREATMENT | MACUCLEAR, INC. | 2016-06-02 | — | — | US | disclosed |
| EP-1951210-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | Elan Pharma International Limited (IE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948135-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | Elan Pharma International Limited (IE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053392-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053393-A2 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070098796-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride | ALKERMES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070098791-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | ALKERMES, INC. | 2007-05-03 | — | — | US | disclosed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098796-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride | HRH2, IDH1, IDH2 | ALDH1A1 1047/4885NPC1 1462/4885RAB9A 3539/4885 |
| US-20070098791-A1 | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | SLC5A11, ATP2A1, QDPR | ALDH1A1 1074/4885NPC1 1786/4885RAB9A 2676/4885 |
| US-20160256400-A1 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | SLC5A11, ATP2A1, QDPR | ALDH1A1 1074/4885NPC1 1786/4885RAB9A 2676/4885 |
| US-20170209381-A1 | Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride | SLC5A11, ATP2A1, QDPR | ALDH1A1 1074/4885NPC1 1786/4885RAB9A 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.